ArticleClinical kidney journal2025
The impact of hemoadsorption in patients with chronic kidney disease undergoing coronary artery bypass grafting.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With an annual incidence of up to 30%, cardiac surgery-associated acute kidney injury (CSA-AKI) may be one of the most underestimated yet common complications, hence reno-protective interventions are critical. We evaluated the impact of hemoadsorption (HA) on clinical outcomes in KDIGO (Kidney Disease: Improving Global Outcomes) G2/A2 patients (GFR 60-89 ml/min/1.73 m Method: Forty patients with chronic kidney disease (KDIGO G2/A2) were treated with intraoperative HA therapy during CABG surgery (HA group) and were compared with 40 propensity-score matched control CABG patients without intraoperative HA (control group). Primary endpoints were the need for renal replacement therapy (RRT) and/or worsening of the KDIGO stage during the perioperative period. Secondary endpoints included changes in inflammatory biomarkers, vasopressor use, and ICU/hospital stay. Results: No significant differences were observed in demographics between groups. Worsened KDIGO stages were more frequent in the control group ( Conclusion: This pioneering study highlights the potential benefits of HA in mitigating kidney function and inflammation in CABG patients with borderline chronic kidney disease. These findings require validation in large, multicenter trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.